Elliot Mathias, MD
Family Medicine · Shelton, CTNPI 1871669978
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$986
- Novo Nordisk$949
- Merck$478
- Lilly USA, LLC$439
- Pfizer$375
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,843100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $1,355 |
| GSK | 61 | $986 |
| Novo Nordisk | 50 | $949 |
| Merck | 30 | $478 |
| Lilly USA, LLC | 23 | $439 |
| Pfizer | 23 | $375 |
| Boehringer Ingelheim | 20 | $335 |
| Amgen | 13 | $236 |
| Sumitomo Pharma America, Inc. | 12 | $229 |
| Abbott | 10 | $211 |
| AstraZeneca | 14 | $193 |
| Exact Sciences | 9 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $112 |
| Amarin Pharma, Inc. | 7 | $102 |
| Biohaven Pharmaceuticals, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $90 |
| Madrigal Pharmaceuticals | 2 | $73 |
| Bayer | 3 | $55 |
| Eisai Inc. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $44 |
| Almatica Pharma LLC | 2 | $33 |
| Medtronic | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Si-bone, Inc. | 1 | $26 |
| Novartis | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Intra-sana Laboratories | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$6,854 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 121 | $151,087 |
| EliquisApixaban | 133 | $143,243 |
| OzempicSemaglutide | 62 | $108,466 |
| JardianceEmpagliflozin | 78 | $103,117 |
| MounjaroTirzepatide | 82 | $94,719 |
| FarxigaDapagliflozin Propanediol | 79 | $80,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $69,674 |
| TradjentaLinagliptin | 32 | $33,017 |
| MyrbetriqMirabegron | 35 | $31,479 |
| TrulicityDulaglutide | 19 | $30,902 |
| GemtesaVibegron | 24 | $27,639 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $18,690 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $16,435 |
| Repatha SureclickEvolocumab | 19 | $14,710 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $478 | $151,087121 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $335 | $149,664136 claims |
| PfizerEliquis | $375 | $143,243133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $439 | $125,621101 claims |
| Novo NordiskOzempic | $949 | $108,46662 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $193 | $92,902110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $986 | $88,36475 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $229 | $27,63924 claims |
| NovartisEntresto | $24 | $7,67911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $90 | $5,29711 claims |
| Sanofi-aventis U.S. LLCPlavix | $21 | $2,91512 claims |
| AbbVieSynthroid | $1,355 | $2,85445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Shelton
- Samuel StreitShelton$13K
- Bharvi BalarShelton$6K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.